Kolexia
Haioun Corinne Médecine générale
Haioun Corinne
Médecine générale
Hôpital Henri Mondor
Créteil, France
520 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Lymphome B Lymphome B diffus à grandes cellules Lymphome folliculaire Maladie de Hodgkin Lymphome malin non hodgkinien Lymphome T Lymphome à cellules du manteau Récidive tumorale locale

Collaborateurs

Voir plus
Tilly Herve
Tilly Herve
Centre Henri-Becquerel, Rouen, France
Salles Gilles
Salles Gilles
Hôpital Lyon Sud, Pierre-Bénite, France
Casasnovas Rene-Olivier
Casasnovas Rene-Olivier
Hôpital François Mitterrand, Dijon, France
Morschhauser Franck
Morschhauser Franck
Centre Hospitalier de Lille, Lille, France

Industries

Voir plus
Abbvie
16 collaboration(s)
Dernière en 2023
Amgen
14 collaboration(s)
Dernière en 2022
Roche
13 collaboration(s)
Dernière en 2023
Incyte
11 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
RELEVANCE: A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY RITUXIMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA The "RELEVANCE" Trial (Rituximab Lenalidomide Versus ANy ChEmotherapy)is Being Conducted as Two Companion Studies: RV-FOL-GELARC-0683 (N=750) and RV-FOL-GELARC-0683C (N=250); the Combined Total of 1000 Patients Enrolled in Both Studies Will be Analyzed.
Essai Clinique (Celgene)   13 mars 2024
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL): A Phase 1/2, Multi-center, Open-label Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of an Orally Available Small Molecule, CC-99282, Alone and in Combination With Anti-Lymphoma Agents in Subjects With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL).
Essai Clinique (Celgene)   04 mars 2024
IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
Haematologica   22 février 2024
Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
Leukemia   10 janvier 2024
Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   18 décembre 2023
R2-CHOP2: A Phase Ib/II Study of Escalating Doses of Revlimid in Association With R-CHOP (R2-CHOP) in the Treatment of B-cell Lymphoma
Essai Clinique (The Lymphoma Academic Research Organisation)   04 décembre 2023
Results of the Phase II of Epirchop Study, Evaluating the Efficacy of Tazemetostat in Combination with R-CHOP in Elderly Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL): A Lysa Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
The CD38/CD3xCD28 Trispecific Antibody (SAR442257) Potentially Represents a Novel Therapeutic Strategy for Peripheral T-Cell Lymphomas
65th ASH Annual Meeting Abstracts   02 novembre 2023
Identification and Clinical Characterization of CNS Relapse in DLBCL Patients across 19 Prospective Phase 2 and 3 Trials - a GLA/ DSHNHL and LYSA Collaboration
65th ASH Annual Meeting Abstracts   02 novembre 2023
Optical Genome Mapping Provides New Molecular Insights in High-Risk Mantle Cell Lymphoma: A Lysa Study
65th ASH Annual Meeting Abstracts   02 novembre 2023